• 1
    Seghal S, Bhatacharya D, Bhardwaj M. Clinical evaluation of purified vero cell rabies vaccine in patients bitten by rabid animals in India. J Comm Dis 1994; 26:139146.
  • 2
    Kositprapa C, Wimalaratna O, Chomchey P, et al. Problems with rabies postexposure management; a survey of 499 public hospitals in Thailand. J Travel Med 1998; 5:3032.
  • 3
    Wilde H. Rabies, 1996. Internat J Infect Dis 1997; 1:135142.
  • 4
    Parviz S, Luby S, Wilde H. Postexposure treatment of rabies in Pakistan. Clin Infect Dis 1998; 27:751756.
  • 5
    Ogunkoya AB, Macconi E. Emergence of antirabies vaccine of unknkown origin in Nigeria. Vaccine 1986; 4:7778.
  • 6
    Mitmoonpitak C, Tepsumethanon V, Wilde H. Rabies in Thailand (veterinary aspects). Epidemiol Infect 1998; 120:165169.
  • 7
    World Health Organization, Expect Committee on Rabies. Report. Geneva : WHO 1992.
  • 8
    World Health Organization. Report of a consultation on intradermal application of human rabies vaccines. WHO, Geneva 1995;WHO/RAB. Res. 95.47.
  • 9
    Chutivongse S, Wilde H, Fishbein DB, et al. One year study of the 2-1-1 intramuscular postexposure rabies vaccine regimen in 100 severely exposed Thai patients using rabies immune globulin and vero cell rabies vaccine. Vaccine 1991; 9:573576.
  • 10
    Vodopija I, Sureau P, Smerdel S, et al. Comparative study of two human diploid cell rabies vaccines administered with antirabies globulin. Vaccine 1998; 6:489490.
  • 11
    Pairoj V. Humoral and cell mediated immune response to a new abbreviated regimen of purified vero cell rabies vaccine. Master of Science Thesis, Graduate School, Chulalongkorn University, Bangkok, Thailand 1998 (ISBN 974-569-393-6).
  • 12
    Lang J, Soerjosembodo S, Simanjuntak G, et al. Suppressant effect of human or equine rabies immunoglobulin on the immunogenicity of postexposure rabies vaccination under the 2-1-1 regimen: a field trial in Indonesia. WHO Bull 1998; 76:491495.
  • 13
    Phanuphak P, Khawplod P, Sirivchayakul S, et al. Humoral and cell-mediated immune response to various economical regimens of purified vero cell rabies vaccine. Asia Pac J Allergy Immunol 1987; 5:3337.
  • 14
    Warrell MJ, Nicholson KG, Warrell DA, et al. Economical multiple site intradermal immunization with human diploid-cell strain vaccine is effective for postexposure rabies prophylaxis. Lancet 1985; 1:10591062.
  • 15
    Chantanakajorntung A, Naraporn N, Khumpkhai W, et al. A post mortality review of human rabies immune globulin manufactured by the Thai Red Cross Society. Vaccine 1998, in press.
  • 16
    Wilde H, Chutivongse S. Equine rabies immune globulin: a product with an undeserved poor reputation. Am J Trop Med Hyg 1990; 42:175178.
  • 17
    Tantawichien T, Benjavongkulchai M, Wilde H, et al. Value of skin test for predicting reaction to equine rabies immune globulin. Clin Infect Dis 1995, 21:660662.
  • 18
    Wilde H, Tipkong P, Sitprija V, Chaiyabutr N. Heterologous antisera and antivenins are essential biologicals; perspectives of a worldwide crisis. Ann Intern Med 1996; 125:233236.
  • 19
    World Health Organization. World survey of rabies No.31. 1997; WHO Geneva, document WHO/EMZOO/97.1.
  • 20
    Wilde H, Sirikawin S, Sabcharoen A, et al. Failure of post-exposure treatment of rabies in children. Clin Infect Dis 1996; 22:228232.
  • 21
    Wilde H. Preexposure rabies vaccination. J Travel Med 1994; 1:5154.
  • 22
    Bernard KW, Fishbein DB, Miller KD, et al. Preexposure rabies immunization with human diploid cell vaccine: decreased antibody responses in persons immunized in developing countries. Am J Trop Med Hyg 1985; 34(3):633645.
  • 23
    Biggs DJ, Schwenke RJ. Longevity of rabies antibody titer in recipients of human diploid cell rabies vaccine. Vaccine 1992; 10:125128.
  • 24
    Kositprapa C, Limsuwun K, Wilde H, et al. Immune response to stimulated postexposure rabies booster vaccination. Clin Infect Dis 1997; 25:614616.
  • 25
    Jaijaroensup W, Limusanno S, Khawplod P, et al. Reliability of rabies postexposure booster injections in subjects who had previously received intradermal preexposure vaccination. J Travel Med 1999, in press.
  • 26
    Narapong N, Khawplod P, Limsuwan K et al. Immune response to rabies booster vaccination in subjects who had postexposure treatment more than five years previously. J Travel Med 1998, in press.
  • 27
    Wilde H, Chutivongse S, Tepsumethanon W, et al. Rabies in Thailand: 1990. Rev Infect Dis 1990; 13:644652.
  • 28
    Matter HC, Schumacher CL, Kharmachit H, et al. Field evaluation of two bait delivery systems for oral immunization of dogs against rabies in Tunesia. Vaccine 1998; 16:657665.
  • 29
    Soon TY. Rabies in Malaysia. Southeast Asian J Trop Med Public Health 1988; 19:535536.
  • 30
    Cleaveland S. The growing problem of rabies in Africa. Trans R Soc Trop Med Hyg 1998; 92:131134.